Ex vivo engineered immune organoids for controlled germinal center reactions

Biomaterials

Volumn 63, Issue , 2015, Pages 24-34

  Purwada, Alberto ^a   Jaiswal, Manish K ^b   Ahn, Haelee ^c   Nojima, Takuya ^d   Kitamura, Daisuke ^d   Gaharwar, Akhilesh K ^b,e   Cerchietti, Leandro ^c   Singh, Ankur ^a  

^a School of Operations Research and Industrial Engineering   (United States)

^b Texas A M University   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e Department of Electrical and Computer Engineering   (United States)

Author keywords

B cell; Class switching; Germinal center; Immuno engineering; Nanocomposite biomaterials; Organoids

Indexed keywords

CELL PROLIFERATION; CELLS; CYTOLOGY; ENZYME ACTIVITY; MAMMALS; NANOCOMPOSITES; NANOSTRUCTURED MATERIALS; T-CELLS; TISSUE;

B CELLS; CLASS-SWITCHING; EXTRACELLULAR MATRICES; GERMINAL CENTER REACTION; GERMINAL CENTERS; MALIGNANT TRANSFORMATIONS; ORGANOIDS; RAPID DIFFERENTIATION;

CELL ENGINEERING;

ANTIBODY; BIOMATERIAL; NANOCOMPOSITE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; CYTOPLASM; EX VIVO STUDY; EXTRACELLULAR MATRIX; GERMINAL CENTER; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; ORGAN CULTURE TECHNIQUE; PROCEDURES; ULTRASTRUCTURE;

ANIMALS; B-LYMPHOCYTES; BIOCOMPATIBLE MATERIALS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; GERMINAL CENTER; MICE, INBRED C57BL; NANOCOMPOSITES; ORGAN CULTURE TECHNIQUES; ORGANOIDS; TISSUE ENGINEERING;

EID: 84939562729     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.06.002     Document Type: Article

References (67)

1. McHeyzer-Williams M., Okitsu S., Wang N., McHeyzer-Williams L. Molecular programming of B cell memory. Nat. Rev. Immunol. 2012, 12:24-34.
2. Berek C., Berger A., Apel M. Maturation of the immune response in germinal centers. Cell 1991, 67:1121-1129.
3. Singh A., Peppas N.A. Hydrogels and scaffolds for immunomodulation. Adv. Mater. 2014, 26:6530-6541.
4. Junt T., Scandella E., Ludewig B. Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat. Rev. Immunol. 2008, 8:764-775.
5. Magri G., Miyajima M., Bascones S., Mortha A., Puga I., Cassis L., et al. Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat. Immunol. 2014, 15:354-364.
6. Cerutti A., Cols M., Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat. Rev. Immunol. 2013, 13:118-132.
7. Zhou P., Shaffer D.R., Alvarez Arias D.A., Nakazaki Y., Pos W., Torres A.J., et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 2014, 506:52-57.
8. Schwickert T.A., Lindquist R.L., Shakhar G., Livshits G., Skokos D., Kosco-Vilbois M.H., et al. In vivo imaging of germinal centres reveals a dynamic open structure. Nature 2007, 446:83-87.
9. Allen C.D., Ansel K.M., Low C., Lesley R., Tamamura H., Fujii N., et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 2004, 5:943-952.
10. Cerchietti L.C., Hatzi K., Caldas-Lopes E., Yang S.N., Figueroa M.E., Morin R.D., et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J. Clin. Invest. 2010, 120:4569-4582.
11. Cerchietti L.C., Ghetu A.F., Zhu X., Da Silva G.F., Zhong S., Matthews M., et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010, 17:400-411.
12. Klein U., Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 2008, 8:22-33.
13. Ame-Thomas P., Le Priol J., Yssel H., Caron G., Pangault C., Jean R., et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 2012, 26:1053-1063.
14. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008, 359:2313-2323.
15. Cayrol F., Diaz Flaque M.C., Fernando T., Yang S.N., Sterle H.A., Bolontrade M., et al. Integrin alphavbeta3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood 2015, 125:841-851.
16. Clozel T., Yang S., Elstrom R., Tam W., Martin P., Kormaksson M., Banerjee S., Vasanthakumar A., Culjkovic B., Scott D., Brennan S., Leser M., Shaknovich R., Chadburn A., Tabbo F., Godley L., Gascoyne R., Borden K., Inghirami G., Leonard J., Melnick A., Cerchietti L. Mechanism-based epigenetic chemosensitization therapy of diffuse large B Cell Lymphoma. Cancer Discov. 2013, 3:1002-1019.
17. De S., Shaknovich R., Riester M., Elemento O., Geng H., Kormaksson M., et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 2013, 9:e1003137.
18. Fontan L., Yang C., Kabaleeswaran V., Volpon L., Osborne M.J., Beltran E., et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 2012, 22:812-824.
19. Cerchietti L.C., Yang S.N., Shaknovich R., Hatzi K., Polo J.M., Chadburn A., et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009, 113:3397-3405.
20. Cerchietti L.C., Lopes E.C., Yang S.N., Hatzi K., Bunting K.L., Tsikitas L.A., et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 2009, 15:1369-1376.
21. Cerchietti L.C., Polo J.M., Da Silva G.F., Farinha P., Shaknovich R., Gascoyne R.D., et al. Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer Res. 2008, 68:3361-3369.
22. Polo J.M., Dell'Oso T., Ranuncolo S.M., Cerchietti L., Beck D., Da Silva G.F., et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 2004, 10:1329-1335.
23. Singh A., Qin H., Fernandez I., Wei J., Lin J., Kwak L.W., et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J. Control. Release: Off. J. Control. Release Soc. 2011, 155:184-192.
24. Qin H., Cha S.C., Neelapu S.S., Lou Y., Wei J., Liu Y.J., et al. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 2009, 114:4142-4149.
25. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., Raz R., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 2005, 11:623-629.
26. Chiarle R., Gong J.Z., Guasparri I., Pesci A., Cai J., Liu J., et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003, 101:1919-1927.
27. Singh A., Suri S., Roy K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 2009, 30:5187-5200.
28. Singh A., Nie H., Ghosn B., Qin H., Kwak L.W., Roy K. Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol. Ther. 2008, 16:2011-2021.
29. Purwada A., Roy K., Singh A. Engineering vaccines and niches for immune modulation. Acta Biomater. 2013, 10:1728-1740.
30. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
31. Heesters B.A., Myers R.C., Carroll M.C. Follicular dendritic cells: dynamic antigen libraries. Nat. Rev. Immunol. 2014, 14:495-504.
32. Song J., Lokmic Z., Lämmermann T., Rolf J., Wu C., Zhang X., et al. Extracellular matrix of secondary lymphoid organs impacts on B-cell fate and survival. Proc. Natl. Acad. Sci. 2013, 110:E2915-E2924.
33. Liu Y.J., Joshua D.E., Williams G.T., Smith C.A., Gordon J., MacLennan I.C. Mechanism of antigen-driven selection in germinal centres. Nature 1989, 342:929-931.
34. Martinez-Valdez H., Guret C., de Bouteiller O., Fugier I., Banchereau J., Liu Y.J. Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2. J. Exp. Med. 1996, 183:971-977.
35. Cerutti A., Zan H., Schaffer A., Bergsagel L., Harindranath N., Max E.E., et al. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+ IgD+ B cell line. J. Immunol. 1998, 160:2145-2157.
36. von Bergwelt-Baildon M.S., Vonderheide R.H., Maecker B., Hirano N., Anderson K.S., Butler M.O., et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002, 99:3319-3325.
37. Schultze J.L., Michalak S., Seamon M.J., Dranoff G., Jung K., Daley J., et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 1997, 100:2757.
38. Coughlin C.M., Vance B.A., Grupp S.A., Vonderheide R.H. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004, 103:2046-2054.
39. Irvine D.J., Stachowiak A.N., Hori Y. Lymphoid tissue engineering: invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Seminars Immunol. 2008, 20:137-146.
40. Suematsu S., Watanabe T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat. Biotechnol. 2004, 22:1539-1545.
41. Wang X., Rodda L.B., Bannard O., Cyster J.G. Integrin-mediated interactions between B cells and follicular dendritic cells influence germinal center B cell fitness. J. Immunol. 2014, 192:4601-4609.
42. Hatzi K., Jiang Y., Huang C., Garrett-Bakelman F., Gearhart M.D., Giannopoulou E.G., et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell. Reports 2013, 4:578-588.
43. Murakami T., Chen X., Hase K., Sakamoto A., Nishigaki C., Ohno H. Splenic CD19-CD35+B220+ cells function as an inducer of follicular dendritic cell network formation. Blood 2007, 110:1215-1224.
44. Rickert R.C., Rajewsky K., Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995, 376:352-355.
45. Nojima T., Haniuda K., Moutai T., Matsudaira M., Mizokawa S., Shiratori I., et al. In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. Nat. Commun. 2011, 2:465.
46. Gorbet M.B., Sefton M.V. Endotoxin: the uninvited guest. Biomaterials 2005, 26:6811-6817.
47. Dolatshahi-Pirouz A., Nikkhah M., Gaharwar A.K., Hashmi B., Guermani E., Aliabadi H., et al. A combinatorial cell-laden gel microarray for inducing osteogenic differentiation of human mesenchymal stem cells. Sci. Rep. 2014, 4:3896.
48. Patel R.G., Purwada A., Cerchietti L., Inghirami G., Melnick A., Gaharwar A.K., et al. Microscale bioadhesive hydrogel arrays for cell engineering applications. Cell. Mol. Bioeng. 2014, 7:394-408.
49. Gaharwar A.K., Avery R.K., Assmann A., Paul A., McKinley G.H., Khademhosseini A., et al. Shear-thinning nanocomposite hydrogels for the treatment of hemorrhage. ACS Nano 2014, 8:9833-9842.
50. Xavier J.R., Thakur T., Desai P., Jaiswal M.K., Sears N., Cosgriff-Hernandez E., et al. Bioactive nanoengineered hydrogels for bone tissue engineering: a growth-factor-free approach. ACS Nano 2015, 9:3109-3118.
51. Fujita T., Kashimura M. Scanning electron microscope studies of human spleen. Surv. Immunol. Res. 1983, 2:375-384.
52. Hirsch S., Guo J., Reiter R., Papazoglou S., Kroencke T., Braun J., et al. MR elastography of the liver and the spleen using a piezoelectric driver, single-shot wave-field acquisition, and multifrequency dual parameter reconstruction. Magn. Reson Med. 2014, 71:267-277.
53. Xing Q., Yates K., Vogt C., Qian Z., Frost M.C., Zhao F. Increasing mechanical strength of gelatin hydrogels by divalent metal ion removal. Sci. Rep. 2014, 4:4706.
54. Stupp R., Hegi M.E., Gorlia T., Erridge S.C., Perry J., Hong Y.K., et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15:1100-1108.
55. Mas-Moruno C., Rechenmacher F., Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 2010, 10:753-768.
56. Lin R.Z., Chen Y.C., Moreno-Luna R., Khademhosseini A., Melero-Martin J.M. Transdermal regulation of vascular network bioengineering using a photopolymerizable methacrylated gelatin hydrogel. Biomaterials 2013, 34:6785-6796.
57. Benton J.A., DeForest C.A., Vivekanandan V., Anseth K.S. Photocrosslinking of gelatin macromers to synthesize porous hydrogels that promote valvular interstitial cell function. Tissue Eng. Part A 2009, 15:3221-3230.
58. Duan B., Hockaday L.A., Kapetanovic E., Kang K.H., Butcher J.T. Stiffness and adhesivity control aortic valve interstitial cell behavior within hyaluronic acid based hydrogels. Acta Biomater. 2013, 9:7640-7650.
59. Vuong B.Q., Lee M., Kabir S., Irimia C., Macchiarulo S., McKnight G.S., et al. Specific recruitment of protein kinase A to the immunoglobulin locus regulates class-switch recombination. Nat. Immunol. 2009, 10:420-426.
60. Shinkura R., Ito S., Begum N.A., Nagaoka H., Muramatsu M., Kinoshita K., et al. Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat. Immunol. 2004, 5:707-712.
61. Liu N., Ohnishi N., Ni L., Akira S., Bacon K.B. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat. Immunol. 2003, 4:687-693.
62. Ruzicka B., Zaccarelli E., Zulian L., Angelini R., Sztucki M., Moussaid A., et al. Observation of empty liquids and equilibrium gels in a colloidal clay. Nat. Mater. 2011, 10:56-60.
63. Gaharwar A.K., Peppas N.A., Khademhosseini A. Nanocomposite hydrogels for biomedical applications. Biotechnol. Bioeng. 2014, 111:441-453.
64. Kerativitayanan P., Carrow J.K., Gaharwar A.K. Nanomaterials for engineering stem cell responses. Adv. Healthc. Mater. 2015, 10.1002/adhm.201500272.
65. Legler D.F., Wiedle G., Ross F.P., Imhof B.A. Superactivation of integrin alphavbeta3 by low antagonist concentrations. J. Cell. Sci. 2001, 114:1545-1553.
66. Kinashi T. Intracellular signalling controlling integrin activation in lymphocytes. Nat. Rev. Immunol. 2005, 5:546-559.
67. Kim J., Kim D.W., Chang W., Choe J., Park C.S., Song K., et al. Wnt5a is secreted by follicular dendritic cells to protect germinal center B cells via Wnt/Ca2+/NFAT/NF-kappaB-B cell lymphoma 6 signaling. J. Immunol. 2012, 188:182-189.